Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 940 Winter Street, Waltham, Massachusetts 02451 (Address of Principal Executive Of ices) (Zip Code) (781) 663-6900 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sciences Access Day - New York City, NY Thursday, February 29, 2024 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 44th Annual Health Care Conference – Boston, MA Monday, March 4, 2024 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Raymond James 45t ...

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, is unveiling the Signals ClinicalTM solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics. This state-of-the-art solution, when integrated with enterprise-class Spotfire visual anal ...

Revvity, Inc. (NYSE:RVTY) Q4 2023 Earnings Conference Call February 1, 2024 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - Chief Executive Officer, President and Director Max Krakowiak - Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research LLC Matthew Sykes - Goldman Sachs Joshua Waldman - Cleveland Research Company LLC Patrick Donnelly - Citigroup Inc. Andrew Cooper - Raymond James Financi ...

Revvity, Inc. (RVTY) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $1.25, which beat the Zacks Consensus Estimate of $1.15 by 8.7%. However, the bottom line declined 12.8% from the year-ago quarter’s level.GAAP EPS from continuing operations was 52 cents compared with 77 cents in the prior-year period. However, GAAP EPS was 64 cents, which includes earnings of 12 cents per share from discontinued operations.Price PerformanceRVTY’s shares have declined 12.6% in the past six months against ...

Revvity (RVTY) reported $695.9 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 36.1%. EPS of $1.25 for the same period compares to $1.70 a year ago. ...

Innovation Transformation Performance 4 -6% y/y COVID: Includes $203M of AES Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink + DD + DD - HSD February 1, 2024 4Q23 Revenue Highlights V -7% | M&A: 0% | FX: 1% 28.0% 18.6% Reported: -8% | M&A: 0% | FX: 1% APPLIED GENOMICS REPRODUCTIVE HEALTH IMMUNODX $376 M 4Q23 revenue +DD -DD -LSD REVENUE AJUSTED OP MARGINS Fourth Quarter 2023 This presentation contains "forw ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The Company reported GAAP earnings per share of $0.64, as compared to $1.01 in the same period a year ago. GAAP revenue for the quarter was $696 million, as compared to $741 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $77 million, as compared to $137 million for the s ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024. “I am pleased to welcome Michael Klobuchar and Sophie Vandebroek to Revvity’s board and look forward to their contributions as we execute on our strategic vision,” said Alexis Michas, non-executive chairman of the board. “Sophie brings deep acumen in AI, business processes, sustainability, and cybersecurity, alon ...

Revvity, Inc. (NYSE:RVTY) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 1:30 PM ET Company Participants Prahlad Singh - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Chase & Co. Rachel Vatnsdal Hi, good afternoon, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JP Morgan. I am joined on stage by Revvity and Prahlad, the CEO. And so as is typical, this is going to be a 40 minute session, it will be roug ...